BRIEF: Airdoc Tech approved for H-share full circulation
Beijing Airdoc Technology Co. Ltd. (2251.HK) announced on Monday that the China Securities Regulatory Commission (CSRC) has approved its plan to convert 50.15 million of its domestic shares into H-shares…
BRIEF: Fosun Pharma raises stake in Henlius
Fosun Pharma (2196.HK) announced on Monday that its wholly owned unit, Fosun Pharma Industrial, acquired 21.03 million unlisted shares of its Henlius (2696.HK) subsidiary for HK$517 million ($66.6 million), or…
BRIEF: Duality Biotherapies surges in Hong Kong trading debut
Shares of biotech firm Duality Biotherapeutics Inc. (9606.HK) opened up 91% at HK$181 on Tuesday and continued to climb in their Hong Kong trading debut, closing up 127% at HK$214.80…
BRIEF: Fangzhou adjusted profit jumps 139% on improving technology, efficiency
Online healthcare platform Fangzhou Inc. (6086.HK) announced last Friday its revenue rose 11.2% last year to 2.71 billion yuan ($374 million). Its annual net loss widened from 197 million yuan…
BRIEF: Hutchmed profit falls on shrinking R&D income
Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), a biopharmaceutical company controlled by CK Hutchison Holdings (0001.HK), said its revenue fell 24.8% last year to $630 million, according to its annual results…
BRIEF: Ping An Healthcare records first annual profit
Ping An Healthcare and Technology Co. Ltd. (1833.HK) on Wednesday reported its revenue rose 2.9% last year to 4.81 billion yuan ($665 million), as it ended years of losses to…
BRIEF: Yonghe Medical’s loss narrows on improved efficiency
Hair transplant specialist Yonghe Medical Group Co. Ltd. (2279.HK) said on Tuesday it expects its net loss for 2024 to narrow significantly to 246 million yuan ($33.73 million) or less,…
Recent Articles
BRIEF: Ant Group eyes Hong Kong listing for overseas unit
9988.HK
BABA.US
BRIEF: Midea buys back 550 million yuan of A-shares in April
0300.HK
000333.SHE
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
IKNA.US
-
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
9969.HK 688428.SHG
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
- Waiting for new industry dawn, SolarSpace turns to IPO for warmth
